Navigation Links
Tailored Treatment Boosts Kidney Cancer Survival
Date:11/1/2008

Study concludes one-size-fits-all therapy needs to be changed

SATURDAY, Nov. 1 (HealthDay News) -- Personalized treatment of kidney cancer patients can increase survival, according to a UCLA study of almost 1,500 patients that identified subsets of kidney cancer that behave differently and need to be treated accordingly.

The UCLA team said their findings indicate the traditional one-size-fits-all treatment approach needs to be changed.

"We have shown that not all kidney cancer patients are the same, not all localized kidney cancers are the same, and not all metastatic kidney cancers are the same," study senior author Dr. Arie Belldegrun, a professor of urology and a researcher at UCLA's Jonsson Comprehensive Cancer Center, said in a UCLA news release.

Patients with localized kidney cancer can have either low-, intermediate-, or high-risk cancers based on the chance for recurrence, the researchers found. Patients with kidney cancer that's spread (metastatic cancer) can also be categorized into similar subsets.

"Now we can base treatment decisions based on that," Belldegrun said.

Patients with localized, low-risk kidney cancer have a projected five-year survival rate of 97 percent and a 10-year survival rate of 92 percent, compared to 81 percent and 61 percent for patients with localized, intermediate-risk cancer, and 62 percent and 41 percent for patients with localized, high-risk cancer.

"All these patients with cancers that have not spread present to their doctors with presumably localized disease, and in the past, they may have been treated the same way. They need to be treated individually, according to their risk levels," Belldegrun said.

For example, the UCLA team showed that surgery alone can produce excellent outcomes in patients with localized, low-risk, kidney cancer, meaning they could be spared the harsh side effects associated with radiation or immunotherapy. But surgery alone isn't sufficient for patients with localized, high-risk kidney cancer.

Patients with metastatic, low-risk cancer should get very aggressive treatment, because there's a good chance the therapy will benefit them. But patients with metastatic, high-risk cancer may choose to decline treatment, because they'll get little or no benefit from it.

"Our paper identifies, very precisely, which patients should get which therapies," Belldegrun said.

The study was published in the Nov. 1 issue of Cancer.

More information

The American Urological Association has more about kidney cancer.



-- Robert Preidt



SOURCE: University of California, Los Angeles, news release, Nov. 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Upscale Seattle-Based Skincare Clinic Expands Into California With Unique Custom Tailored Skincare Approach
2. Suboxone Fast Passing Methadone As Preferred Method Of Treatment For Opiate Detox
3. ENT doctors release national guideline on treatment for common cause of dizziness
4. Landmark UCLA study finds aggresive, personalized treatment increases kidney cancer patient survival
5. Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding
6. Health Secretary Raises Awareness About Diabetes; Rising Costs of Treatment
7. If metastasectomy should be performed before other treatments
8. A useful imaging modality for monitoring treatment response to hepatocellular carcinoma
9. Combo Treatment Best for Anxiety Disorder in Kids
10. Researchers identify mechanism, possible drug treatment for tumors in neurofibromatosis
11. PURE Bioscience Granted US Patent on SDC for Food Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tailored Treatment Boosts Kidney Cancer Survival
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
Breaking Medicine Technology: